Obermatt
See Similar Stocks →

Krystal Biotech

NSQ:KRYS · US5011471027
BiotechnologyMedium

360

96
EV / EBIT30
Price / Owner Earnings12
Owner Earnings Yield82
Dividend Yield1
Price/Sales25
EV / Gross Profit30
Price/Book33
Return on Capital86
Cash Return on Capital87
Return on Equity85
EBIT Margin97
Gross Profitability57
Cash Conversion51
Accruals47
Owner Earnings Margin92
Sales growth73
Profit Growth91
Long-Term EPS Growth96
Owner Earnings Growth76
Reinvestment74
Price momentum89
Debt load95
Refinancing65
Debt Payback100
Liquidity—
Analyst ratings79
Opinion Changes50
Price Target Upside12
Market mood100
Value Creation18/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Krystal Biotech generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2017
Employees270
Websitekrystalbio.com
ISINUS5011471027
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DermatologyGeneticsRespiratoryOphthalmologyOncologyGenetic DisorderBiopharmaBiotechnologyHealth Care

Description

Krystal Biotech, Inc. operates as a fully integrated, global, commercial-stage biotechnology company. The company focuses on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medi…

Analysis

Quality compounder

Krystal Biotech, Inc. earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.

On valuation, the picture is expensive. The owner-earnings multiple stands at 44.2×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 17% a year, against analyst forecasts of 63%. The price, in other words, assumes less than the experts do.

Growth is solid; the safety picture is sturdy. The company scores 18/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

Similar Stocks

The companies this stock is ranked against.

Compare Krystal Biotech with its peers
PTC Therapeutics
NSQ:PTCT
12
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Sarepta Therapeutics
NSQ:SRPT
69
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Enanta Pharmaceuticals
NSQ:ENTA
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Karyopharm Therapeutics
NSQ:KPTI
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tarsus Pharmaceuticals
NSQ:TARS
29
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Rezolute
NAQ:RZLT
53
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →